Biotech By Allison DeAngelis Apollo acquires minority stake in Sofinnova, extending private equity dealmaking in life sciences
Pharmalot By Ed Silverman Greece plans to go to court to seek compensation from Novartis over a bribery scandal
Pharmalot By Ed Silverman Pharmalittle: FDA OKs new type of diabetes drug from Lilly; Early-stage biotechs are juicy targets for M&A surge
Biotech By Meghana Keshavan Theranos tries to quell doubts with new blood test platform, but shows scant data
Biotech By Meghana Keshavan Embattled Theranos promises first-ever peek at its science — but doubts abound
Pharmalot By Ed Silverman Pharmalot, Pharmalittle: Biogen CEO to leave, Theranos hires compliance execs
Pharmalot By Ed Silverman Pharmalot, Pharmalittle: Purdue delayed reporting excessive OxyContin prescribing
Biotech By Megan Thielking Theranos CEO Elizabeth Holmes banned for two years from industry she aimed to transform
Special Report By Charles Piller ‘Silicon Valley arrogance’? Google misfires as it strives to turn Star Trek fiction into reality
Pharmalot By Ed Silverman Pharmalot, Pharmalittle: Odds of an early-stage biotech drug winning approval are slim
Business By Rebecca Robbins and Meghana Keshavan Theranos plans bold expansion even as it reels from new setbacks
Politics By Rebecca Robbins When does hyping a product become a criminal act? Theranos may be about to find out
Business By Rebecca Robbins Theranos CEO Elizabeth Holmes faces possible two-year ban from blood-testing industry
Pharmalot By Ed Silverman Pharmalot, Pharmalittle: Walgreens threatens to terminate Theranos partnership
Pharmalot By Ed Silverman Pharmalot, Pharmalittle: Roche internal investigation, problems at Theranos lab
Business By Rebecca Robbins The Theranos scandal should be a wake-up call. Here are 4 reasons it won’t be
Pharmalot By Ed Silverman Pharmalot, Pharmalittle: US prices higher for top-selling drugs, FDA investigating Theranos